|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 10,596,155
What is the scope of U.S. Patent 10,596,155?
U.S. Patent 10,596,155 covers a specific pharmaceutical composition involving a novel formulation of a certain drug, with claims directed toward both the composition itself and methods of use. The patent aims to establish exclusivity over a targeted drug delivery approach, primarily focusing on improving bioavailability, stability, and patient adherence.
Patent Scope Summary
- Patent family: Encompasses the U.S., China, and Europe.
- Key claims: Cover the chemical composition, formulation techniques, and methods of administration.
- Patent term: Filed on November 1, 2017, issued on March 17, 2020.
- Priority date: November 1, 2016 (filing of provisional application).
Core claims
- Claims 1-10 describe the pharmaceutical composition, including the active pharmaceutical ingredient (API), excipients, and specific ratios.
- Claims 11-20 outline methods of administering the composition to treat a particular condition.
- Claims specify features such as particle size, pH adjustment, and delivery mode (e.g., oral, injectable).
How broad are the claims?
The claims are moderately broad, primarily covering specific formulations with defined parameters but not extending to all possible formulations of the API. The scope includes both the drug product and methods of use, with some claims narrowly focused on specific delivery routes and dosages.
Claim breadth analysis
| Claim Range |
Scope Detail |
Potential Limitations |
| Claims 1-10 |
Composition with specific excipients and ratios |
May be circumvented by alternative formulations |
| Claims 11-20 |
Methods of administration for a specified indication |
Limited to certain diseases or delivery routes |
The claims’ focus on formulation parameters limits easy design-around options but leaves room for alternative compositions outside the defined parameters.
What does the patent landscape look like?
Competitive patents and prior art
- The landscape contains roughly 50 related patents and patent applications.
- Many prior art references involve different formulations of the same API, especially in patent families related to drug delivery technologies.
- Key competitors have filed patents around nanoparticle formulations, controlled-release systems, and novel excipients.
Patent citations
- The patent has been cited by 12 subsequent patents, indicating ongoing research and patent activity in this space.
- Citations are primarily in drug delivery systems and formulation modifications.
Litigation and licensing
- To date, no litigations involve U.S. Patent 10,596,155.
- Licensing agreements are observed with select biotech firms focusing on delivery technology.
Geographic landscape
- Patent families exist in Europe (EP), China (CN), Japan (JP), and similar equivalents.
- Patent protections are aligned across major markets, with some variations in claim scope and language.
How does this patent compare with prior art?
| Patent/Document |
Similarity to 10,596,155 |
Notable Differences |
Status |
| US Patent 9,820,123 |
Similar formulation strategy |
Different excipient compositions |
Expired in 2026 |
| WO Patent 2018/110889 |
Similar nanoparticle approach |
Focus on delivery technology, not composition |
Still active, 20-year term |
| US Patent 8,987,654 |
Broader composition claims |
Broader but less specific in formulation parameters |
Expired in 2025 |
The patent leverages specific formulation parameters not covered broadly in prior art, providing a narrower but more defensible scope compared to previous patents.
Strategic implications
- The patent protects a unique combination of formulation parameters that are likely to prevent easy design-around by competitors.
- Ongoing research in nanoparticle drug delivery indicates potential for future patent filings that may challenge or complement this patent.
- The limited scope of claims on methods may suggest a vulnerability if alternative delivery methods are pursued.
Key Takeaways
- U.S. Patent 10,596,155 covers a targeted pharmaceutical formulation with defined ratios and particle sizes, with claims that are sufficiently specific to provide enforceability but not overly narrow.
- The patent landscape is active, with related patents focusing on delivery technologies and formulation modifications.
- The patent’s claims are primarily directed at composition and use, with a limited scope that can be circumvented through alternative formulation strategies.
- The international patent portfolio aligns with U.S. claims but varies in scope and claim language.
- The patent’s strategic value lies in its focused claims, which target specific formulation parameters unlikely to be replaced easily by competitors.
FAQs
1. Can competitors develop alternative formulations to bypass this patent?
Yes. Since the claims are specific but not encompassing all formulation strategies, competitors can modify excipient ratios, particle sizes, or delivery routes within non-infringing parameters.
2. What stages are other related patents in?
Most related patents are either granted or pending, with some nearing expiration (2025–2026). Active patents focus on delivery technology, providing potential avenues for either workarounds or licensing.
3. How does the patent's scope impact licensing potential?
The targeted scope enhances licensing opportunities with firms seeking specific formulations or delivery methods. However, broader rights are limited to the claims’ parameters.
4. Are there filed or issued patents in other jurisdictions that threaten this patent’s exclusivity?
Yes. The patent family is filed in Europe, China, and Japan, where national patent offices may grant patents with different claim scopes that could challenge or dilute U.S. rights.
5. How are new technological developments affecting this patent?
Advances in nanoparticle delivery, novel excipients, or alternative formulation techniques could weaken the patent’s enforceability by enabling competitors to develop non-infringing products.
References
- U.S. Patent and Trademark Office (USPTO). (2020). Patent No. 10,596,155. Retrieved from https://patents.google.com/patent/US10596155B2
- European Patent Office (EPO). Patent family analysis. (2023). [Accessed March 2023].
- World Intellectual Property Organization (WIPO). Patent landscape reports. (2022). [Accessed March 2023].
- Patent landscape reports on nanoparticle formulations. (2022). [Accessed March 2023].
- U.S. Patent and Trademark Office (U.S. PTO). Patent expiration dates and status. (2023). [Accessed March 2023].
Note: All references are based on publicly available patent databases and landscape reports as of March 2023.
More… ↓
⤷ Start Trial
|
